Accuray CyberKnife system real world data and clinical studies show benefits in treatment of neurological indications
July 13, 2022
SUNNYVALE, Calif., July 12, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new clinical studies presented at the 15th Congress of the International Stereotactic Radiosurgery Society (ISRS) in Milan, Italy reinforce the value of the company's CyberKnife® platform in the treatment of neurological indications with non-invasive radiosurgery. The data highlight the benefits experienced by neurosurgeons for more than two decades, including the ability to effectively and efficiently deliver radiation in single and multi-fraction sessions, treat benign and functional cases, primary brain and spine tumors and metastases, as well as previously irradiated tumors.
"We are proud to see the impact that CyberKnife technology has on advancing patient care, with nearly 50 abstracts presented at the ISRS conference showcasing the system's use for non-invasive radiosurgery treatments. The data indicate we are fulfilling our goal to offer clinicians the tools they need to enhance the quality of care they offer and provide additional treatment options to their patients," said Suzanne Winter, president and chief executive officer of Accuray.
Ms. Winter continued, "The CyberKnife platform continues to evolve with powerful enhancements that enable clinicians to continue delivering extremely precise and accurate radiosurgery treatments, while also significantly reducing treatment times, providing a more comfortable experience for patients and enabling medical care teams to treat more patients each day. But we are not stopping here. Through investments in research and development and industry partnerships we will continue to introduce best-in-class innovations that make an incredible system even better."
New CyberKnife System Data: Helping to Make a Clinical Difference for Patients in as little as 1 to 5 Treatments
The CyberKnife System delivers frameless radiosurgery treatments, unlike other systems that use a fixed metal frame attached to the patient's head to prevent movement during treatment. It provides clinical teams with a device that maximizes patient comfort and can deliver precision treatments in a single session, as well as up to 5 ultra-hypofractionated treatments, expanding access to radiosurgery to more patients. Studies shared at the ISRS meeting indicate radiosurgery delivered with the CyberKnife System can:
Provide excellent local control with very low toxicity when treating perioptic meningiomas, tumors that are challenging to treat because of their close proximity to critical brain structures impacting a person's vision1
Offer a feasible and effective technique for treating patients who have previously received radiation treatment for recurrent primary brain tumors and metastases - indications with limited treatment options2
Supply an effective treatment approach for patients with craniopharyngioma, a slow growing brain tumor, with no evidence of long-term complications such as deterioration of visual or neuroendocrine function3
Provide clinical teams with an effective single fraction or ablative option, with low toxicity, for the post-operative treatment of brain metastases4
The CyberKnife System is the industry's only radiation delivery system that features a linear accelerator (linac) directly mounted onto a sophisticated robotic platform to deliver radiation therapy. The robot maneuvers around the patient to deliver multiple beams of radiation from thousands of angles to target the tumor or lesion. Using advanced imaging and Accuray proprietary Synchrony® technology, the system can see the tumor or lesion in the brain and continually verifies its position, automatically correcting and adapting the beam position for even the slightest movement. For example, if the patient moves their head during treatment, the CyberKnife® System detects this movement and synchronizes the treatment target to the new position in real-time delivering maximum dose directly to the tumor while minimizing dose to surrounding health tissue, reducing the risk of many common side effects.
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide.
SOURCE Accuray Incorporated